Lyme Vaccine Shows Promise, but 'Tricky' Path Lies Ahead
newser.com • • business
Key Points:
- Pfizer and Valneva's experimental Lyme disease vaccine demonstrated over 70% effectiveness in a late-stage trial involving 9,400 participants aged 5 and older, prompting plans to seek regulatory approval.
- The trial's results, showing 73.2% real-world effectiveness compared to placebo, are promising but inconclusive due to a low number of Lyme disease cases among participants.
- The new vaccine is similar to LYMErix, a vaccine approved in 1998 that was withdrawn after safety concerns and low demand, raising skepticism about regulatory approval prospects.
- Lyme disease remains a significant health issue in the US, affecting approximately 476,000 people annually and potentially causing serious long-term complications if untreated.
